Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces that get modified by inflammation. Even while on a high-fat diet, the antibody protected the mice from arterial plaque formation, hardening of the arteries and liver disease, and prolonged their lives.
This study, published June 6 by Nature, marks the first demonstration in a living system that OxPL triggers inflammation and leads to plaque formation. The results also suggest a new approach for preventing or reversing a number of inflammatory diseases.
“Wherever you get inflammation, you get OxPL,” said senior author Joseph Witztum, MD, professor of medicine at UC San Diego School of Medicine. “It doesn’t mean OxPL is the cause, but it definitely plays a major role.” Witztum led the study with first author Xuchu Que, PhD, a senior project scientist at UC San Diego School of Medicine.
Some phospholipids — the molecules that make up cell membranes — are prone to modification by reactive oxygen species, forming OxPL. This event is particularly common in inflammatory conditions such as atherosclerosis, in which artery-blocking plaques form. Prior to this study, researchers were unable to control phospholipid oxidation in a way that would allow them to study its role in inflammation and atherosclerosis.
Witztum, Que and team engineered mice with two special attributes: 1) they have a gene mutation that makes them a good model for atherosclerosis and 2) they generate a piece of an antibody called E06 that’s just enough to bind OxPL and prevent their ability to cause inflammation in immune cells, but not enough to cause inflammation on its own. They fed the mice a high-fat diet.
Here’s what happened: Compared to control mice, the mice with E06 antibodies had 28 to 57 percent less atherosclerosis, even after one year and despite having high levels of cholesterol. The antibody also decreased aortic valve calcification (hardening and narrowing of the aortic valves), hepatic steatosis (fatty liver disease) and liver inflammation. E06 antibody-producing mice had 32 percent less serum amyloid A, a marker of systemic inflammation.
The E06 antibody also prolonged the life of the mice. After 15 months, all of the E06 antibody-producing mice were alive, compared to 54 percent of the control mice.
“We showed for the first time that OxPL are truly pro-inflammatory and pro-atherogenic and, moreover, that they can be counteracted by E06 antibody,” Witztum said. “This suggests that therapies that inactivate OxPL may be beneficial for reducing inflammation in general, and in particular in the case of diseases such as atherosclerosis, aortic stenosis and hepatic steatosis.”
Witztum and team are now testing E06 antibody in mouse models of human diseases linked to inflammation, such as osteoporosis (bone loss) and nonalcoholic steatohepatitis (NASH, a type of liver disease).
Receive an email update when we add a new INFLAMMATION article.
The Latest on: Inflammation
via Google News
The Latest on: Inflammation
- The inflammation-busting ACV tonic Massy Arias blends up in the mornings on November 12, 2018 at 12:57 pm
Doing your skin-care regimen twice a day—once in the morning and once before bed—is pretty standard. But having a regular workout routine shakes everything up and adds more to the equation. After swea... […]
- Subclinical Heart Inflammation Seen in RA on November 12, 2018 at 10:36 am
A study using 18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) found that rheumatoid arthritis (RA) disease activity was correlated with more myocardial inflammation ... […]
- New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation on November 12, 2018 at 3:30 am
Additional analysis of the Phase II IC data confirmed the optimal dosing regimen of PLX-PAD in the treatment of peripheral arterial diseases (PAD) - two administrations of 300 million cells, each orig... […]
- AHA: Targeting Inflammation With Methotrexate Flops for CV Prevention on November 10, 2018 at 2:04 pm
CHICAGO -- Low-dose methotrexate given to reduce inflammation had no impact on cardiovascular events in high-risk but stable atherosclerosis, the CIRT randomized trial showed. A weekly dose of 15 to 2... […]
- Generic arthritis drug comes up short against inflammation in heart disease on November 10, 2018 at 1:51 pm
Giving a generic anti-inflammatory drug widely used to treat rheumatoid arthritis to people who previously had a heart attack or stroke worked no better than placebo in preventing another cardiovascul... […]
- Inflammation Marker Prognostic in DLBCL on November 8, 2018 at 2:17 pm
Higher rates of the inflammation marker erythrocyte sedimentation rate (ESR) was associated with several unfavorable characteristics of and worse survival from diffuse large B-cell lymphoma (DLBCL), a... […]
- What fights inflammation, boosts collagen, and relieves pain? Echinacea—and that’s only half its health benefits on November 7, 2018 at 11:25 pm
There are so many supplements that you could be taking at any given time—for your skin, for your hair, for your bloat, or even for better sleep, that it can become confusing to remember which does wha... […]
- Inflammation Can Steal Your Sleep on November 7, 2018 at 1:31 pm
The circadian rhythm, the body’s natural time-keeper, when kept in good working order can help to sustain a healthy state. When the circadian rhythm is altered any of the many contributing factors, th... […]
- How Reducing Inflammation Can Help Manage Psoriasis on November 7, 2018 at 8:03 am
Although the exact cause of psoriasis is still a matter of debate in the medical world, a theory that’s backed up by an ever-increasing amount of research is that inflammation in the body can lead to ... […]
via Bing News